Background Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin
lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. Objectives …

Objective. To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical
practice setting. Methods. Clinical data for all adult patients with multiple sclerosis (MS) …

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte
depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS) …

Objective: B cells and the humoral immune system have been implicated in the
pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Introduction Rituximab is considered as a potential therapeutic option in relapsing-remitting
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the …

Objective: To investigate the efficacy of rituximab as rescue therapy in patients with
relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by …

Background Rituximab is increasingly being used in treatment of multiple Sclerosis (MS) in
our centers due to its easy availability, efficacy and favorable side effect profile. Here we …

Objectives The use of rituximab (RTX) in multiple sclerosis (MS) is a rapidly increasing
choice of disease‐modifying therapy. Efficacy outside specialized university hospital‐based …

In multiple sclerosis (MS), the presence of B cells, plasma cells and excess
immunoglobulins in central nervous system lesions and in the cerebrospinal fluid implicate …